Karuna Therapeutics, Inc. (KRTX)
| Market Cap | 3.26B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -68.55M |
| Shares Out | 29.46M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $114.89 |
| Previous Close | $111.60 |
| Change ($) | 3.29 |
| Change (%) | 2.95% |
| Day's Open | 112.85 |
| Day's Range | 110.17 - 116.73 |
| Day's Volume | 107,380 |
| 52-Week Range | 69.58 - 146.97 |
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced the pricing of an underwritten public offering.
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing hi...
BOSTON--(BUSINESS WIRE)---- $KRTX #NEJM--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychi...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ:KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
BOSTON & PARAMUS, N.J.--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc.
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transfor...
Karuna Therapeutics (KRTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Karuna Therapeutics (KRTX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also witnessed a a rally since Mar 23.
As of late, it has definitely been a great time to be an investor in Karuna Therapeutics, Inc. (KRTX).
COVID-19 and initial public offerings don’t go well together.
The volatile biotech has been up and down since its massive gain back in November.
The biotech's biggest shareholder just made a move that rattled Karuna's other shareholders.
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for investors who ...
This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.
An index that tracks initial public offerings has outperformed the S&P 500 in what could be a historic year for stocks.
Is the stock a buy now that the price has dropped?
These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?
In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.
4 Biotech Neurology Stocks, As Biotechs March On
Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock.
As of late, it has definitely been a great time to be an investor Karuna Therapeutics
Karuna's Drug Mechanism Of Action Established After Latest Positive Trial Readout In Schizophrenia Study
Karuna Therapeutics Tests Our Theories!
Karuna Therapeutics: Fundraising Makes For Buying Opportunity
"We're cautiously optimistic given the robustness of the clinical data that we reported this week," Karuna Therapeutics CEO Dr. Steve Paul says.
Karuna Therapeutics soars on potentially 'game changing' new schizophrenia drug
Karuna CEO Dr.
History is littered with promising phase 2 drugs that failed upon further testing. Investors shouldn't get caught up in the hype.
The pharma company announced the pricing of a public stock offering.
Positive clinical trial results recently sent this stock soaring, but can it climb further?
Karuna Therapeutics Inc. (NASDAQ: KRTX) shares skyrocketed on Monday after the firm announced mid-stage results from its schizophrenia treatment.
Shares of Karuna Therapeutics have septupled in value over two days after the biotech company's schizophrenia treatment succeeded in a midstage test.
The great news from a clinical study of experimental schizophrenia drug KarXT still has investors excited about the biotech stock.
About KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the t... [Read more...]
| Industry Biotechnology | IPO Date Jun 28, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol KRTX |
Analyst Forecasts
According to 12 analysts, the average rating for KRTX stock is "Strong Buy." The 12-month stock price forecast is 161.38, which is an increase of 40.46% from the latest price.